Uncategorized

HUIDAGENE ANNOUNCES IND APPROVAL OF THE FIRST CHINA MULTI-REGIONAL, MULTI-NATIONAL MASTER PROTOCOL OF HG004 BY NMPA

HuidaGene Therapeutics announces that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved its investigational new drug (IND) application for the planned multi-regional, multi-national clinical trial of HG004.

HUIDAGENE ANNOUNCES IND APPROVAL OF THE FIRST CHINA MULTI-REGIONAL, MULTI-NATIONAL MASTER PROTOCOL OF HG004 BY NMPA Read More »

Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL

Phio Pharmaceuticals Corp. today announced that in vivo data from a mouse model of colon cancer demonstrates target synergy-enhanced anti-tumor efficacy from a novel dual-targeting mouse PD-1 and CTLA-4 of an INTASYL coformulation.

Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL Read More »

Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics

Coeptis Therapeutics Holdings, Inc. announced it has entered into a binding term sheet with Deverra Therapeutics, Inc. (“Deverra Therapeutics”) pursuant to which it has obtained an exclusive right, until August 31, 2023.

Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics Read More »

Pre-Clinical Data of Palatin’s Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular Sciences

Palatin Technologies, Inc. today announced The International Journal of Molecular Sciences published a manuscript, “Stimulating the Melanocortin System in Uveitis and Diabetes Preserves the Structure and Anti-Inflammatory Activity of the Retina” by Tat Fong Ng and Andrew W. Taylor from Department of Ophthalmology, Boston University Chobanian and Avedisian School of Medicine, in Boston, Massachusetts.

Pre-Clinical Data of Palatin’s Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular Sciences Read More »

Nordic Nanovector Publishes Data from the PARADIGME Phase 2 Clinical Trials with Betalutin® on European Clinical Trials Database

Nordic Nanovector ASA announces that full results from its Phase 2 clinical trials of Betalutin® in resistant/refractory indolent non-Hodgkin’s lymphoma have been published at EudraCT, the European Union Drug Regulating Authorities Clinical Trials Database of the European Union.

Nordic Nanovector Publishes Data from the PARADIGME Phase 2 Clinical Trials with Betalutin® on European Clinical Trials Database Read More »

Scroll to Top